Mkts

Cytokinetics, Incorporated

NASDAQ: CYTK
$51.32-0.33 (-0.64%)
As of Nov 18, 4:00 PM ET

Key statistics

Day range
51.0052.84
52-week range
51.3788.31
Today
Open51.48
Previous close51.32
Volume—
Valuation
Market cap7.20B
P/E ratio—
EPS (TTM)-6.04
Income & risk
Dividend / yield—
Beta0.46
Avg volume1.96M
Discussion

CYTK News

Stories mentioning CYTK from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue19,35517,7551,93666,7691,57916,927463.00249.00
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development95,525105,97799,233112,55498,26293,62984,61279,597
Sales General & Admin104,89657,369
Total Operating Expenses202,973196,121168,691178,275157,210155,967141,264130,421
Operating Income (Loss)(183,618)(178,366)(166,755)(111,506)(155,631)(139,040)(140,801)(130,172)
Interest Income
Interest Expense11,35311,0848,9388,92812,732
Other Expense
Pretax Income
Tax Provision
Net Income (Loss)(206,031)(183,031)(306,178)(134,370)(161,376)(150,020)(160,545)(143,318)
Earnings Per Share (Basic)(1.67)(1,525)(2.55)(1.12)(1.36)(1,339)(1.36)(1.31)
Earnings Per Share (Diluted)(1.67)(1,525)(2.55)(1.12)(1.36)(1,339)(1.36)(1.31)
Weighted Average Shares Outstanding (Basic)123.00120.00120.00119.00118.00112.00118.00109.00
Weighted Average Shares Outstanding (Diluted)123.00120.00120.00119.00118.00112.00118.00109.00

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About CYTK

Cytokinetics, Incorporated (NASDAQ: CYTK) is a stock listed on the Nasdaq Stock Market under the ticker symbol CYTK. It last traded at $51.32 (Nov 18, 2026, 4:00 PM ET), down 0.6% on the day. That gives Cytokinetics a market capitalisation of $7.2B.

Over the past 52 weeks CYTK has traded between $51.37 and $88.31.

Revenue for the quarter ended Mar 31, 2026 was $19.4M; a net loss of $206.0M. Revenue was up 1126% from $1.6M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$19.4M-$206.0M-1064.5%
Dec 31, 2025$17.8M-$183.0M-1030.9%
Sep 30, 2025$1.9M-$306.2M-15815.0%
Jun 30, 2025$66.8M-$134.4M-201.2%

From Cytokinetics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…